{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:08:27Z","timestamp":1784243307109,"version":"3.55.0"},"reference-count":34,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2024,2,12]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Many individuals with rheumatic disease are at higher risk for severe acute coronavirus disease 2019 (COVID-19). We aimed to evaluate risk factors for postacute sequelae of COVID-19 (PASC) using an electronic health record (EHR)-based definition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified patients with prevalent rheumatic diseases and COVID-19 within the Mass General Brigham healthcare system. PASC was defined by the International Classification of Diseases, 10th revision (ICD-10) codes, relevant labs, vital signs, and medications at least 30 days following the first COVID-19 infection. Patients were followed until the earliest of incident PASC, repeat COVID-19 infection, 1 year of follow-up, death, or February 19, 2023. We used multivariable Cox regression to estimate the association of baseline characteristics with PASC risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 2459 patients (76.37% female, mean age 57.4 years), the most common incident PASC manifestations were cough (14.56%), dyspnea (12.36%), constipation (11.39%), and fatigue (10.70%). Serious manifestations including acute coronary disease (4.43%), thromboembolism (3.09%), hypoxemia (3.09%), stroke (1.75%), and myocarditis (0.12%) were rare. The Delta wave (adjusted hazard ratio [aHR] 0.63, 95% CI 0.49-0.82) and Omicron era (aHR 0.50, 95% CI 0.41-0.62) were associated with lower risk of PASC than the early pandemic period (March 2020\u2013June 2021). Age, obesity, comorbidity burden, race, and hospitalization for acute COVID-19 infection were associated with greater risk of PASC. Glucocorticoid (GC) use (aHR 1.19, 95% CI 1.05-1.34 compared to no use) was associated with greater risk of PASC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Among patients with rheumatic diseases, following their first COVID-19 infection, we found a decreased risk of PASC over calendar time using an EHR-based definition. Aside from GCs, no specific immunomodulatory medications were associated with increased risk, and risk factors were otherwise similar to those seen in the general population.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.2023-1092","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T13:25:14Z","timestamp":1709299514000},"page":"529-537","source":"Crossref","is-referenced-by-count":8,"title":["Factors Associated With an Electronic Health Record\u2013Based Definition of Postacute Sequelae of COVID-19 in Patients With Systemic Autoimmune Rheumatic Disease"],"prefix":"10.3899","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6038-0346","authenticated-orcid":false,"given":"Naomi J.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily N.","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.M.","family":"Vanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishan","family":"Guzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina J.","family":"Bade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alene","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rathnam","family":"Venkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi","family":"Srivatsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary K.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Hanberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2423-5982","authenticated-orcid":false,"given":"Yumeko","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail E.","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5556-4618","authenticated-orcid":false,"given":"Jeffrey A.","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4708-7038","authenticated-orcid":false,"given":"Zachary S.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"2024050105200873000_51.5.529.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.1181"},{"key":"2024050105200873000_51.5.529.2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.41619","article-title":"COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study","volume":"73","author":"D\u2019Silva","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024050105200873000_51.5.529.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219279"},{"key":"2024050105200873000_51.5.529.4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/acr2.11386","article-title":"Coronavirus disease 2019 outcomes among recipients of anti-CD20 monoclonal antibodies for immune-mediated diseases: a comparative cohort study","volume":"4","author":"Patel","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2024050105200873000_51.5.529.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217871"},{"key":"2024050105200873000_51.5.529.6","doi-asserted-by":"crossref","first-page":"e430","DOI":"10.1016\/S2665-9913(22)00096-0","article-title":"Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis","volume":"4","author":"Widdifield","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2024050105200873000_51.5.529.7","doi-asserted-by":"crossref","first-page":"102243","DOI":"10.1016\/j.coph.2022.102243","article-title":"Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases","volume":"65","author":"Paik","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"2024050105200873000_51.5.529.8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002187"},{"key":"2024050105200873000_51.5.529.9","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.2002063"},{"key":"2024050105200873000_51.5.529.10","doi-asserted-by":"publisher","DOI":"10.7326\/M21-1757"},{"key":"2024050105200873000_51.5.529.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.3685"},{"key":"2024050105200873000_51.5.529.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.269"},{"key":"2024050105200873000_51.5.529.13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.41914","article-title":"Humoral and cellular immune responses to SARS-CoV-2 infection and vaccination in autoimmune disease patients with B cell depletion","volume":"74","author":"Simon","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2024050105200873000_51.5.529.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220647"},{"key":"2024050105200873000_51.5.529.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.1237"},{"key":"2024050105200873000_51.5.529.16","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18052621"},{"key":"2024050105200873000_51.5.529.17","unstructured":"World Health Organization . A clinical case definition of post COVID-19 condition by a Delphi consensus. [Internet. Accessed February 22, 2024.] Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1"},{"key":"2024050105200873000_51.5.529.18","unstructured":"Centers for Disease Control and Prevention . Post-COVID conditions: information for healthcare providers. [Internet. Accessed February 22, 2024.] Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/post-covid-conditions.html"},{"key":"2024050105200873000_51.5.529.19","doi-asserted-by":"crossref","first-page":"101402","DOI":"10.1016\/j.beha.2022.101402","article-title":"COVID-19 and antiphospholipid antibodies","volume":"35","author":"Butt","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"key":"2024050105200873000_51.5.529.20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.8823"},{"key":"2024050105200873000_51.5.529.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223439"},{"key":"2024050105200873000_51.5.529.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01840-0"},{"key":"2024050105200873000_51.5.529.23","unstructured":"Centers for Disease Control and Prevention . Stay up to date with COVID-19 vaccines. [Internet. Accessed February 22, 2024.] Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/stay-up-to-date.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvaccines%2Ffully-vaccinated.html"},{"key":"2024050105200873000_51.5.529.24","doi-asserted-by":"crossref","first-page":"152108","DOI":"10.1016\/j.semarthrit.2022.152108","article-title":"Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: a cohort study","volume":"58","author":"Patel","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2024050105200873000_51.5.529.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152025"},{"key":"2024050105200873000_51.5.529.26","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002587"},{"key":"2024050105200873000_51.5.529.27","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/S2665-9913(23)00066-8","article-title":"Post-COVID-19 condition in patients with autoimmune rheumatic diseases: the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study","volume":"5","author":"Sen","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2024050105200873000_51.5.529.28","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-022-01909-W"},{"key":"2024050105200873000_51.5.529.29","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s11606-022-07997-1","article-title":"Racial\/ethnic disparities in post-acute sequelae of SARS-CoV-2 infection in New York: an EHR-based cohort study from the RECOVER program","volume":"38","author":"Khullar","year":"2023","journal-title":"J Gen Intern Med"},{"key":"2024050105200873000_51.5.529.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01283-z"},{"key":"2024050105200873000_51.5.529.31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/acr.25200","article-title":"Long COVID in persons with self-reported arthritis: symptoms, associated factors, and functional limitations","volume":"76","author":"Feldman","year":"2024","journal-title":"Arthritis Care Res"},{"key":"2024050105200873000_51.5.529.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00964-y"},{"key":"2024050105200873000_51.5.529.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00460-6"},{"key":"2024050105200873000_51.5.529.34","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7232a3"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2023-1092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T15:03:33Z","timestamp":1714575813000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2023-1092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,1]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.3899\/jrheum.2023-1092"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2023-1092","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}